TWI460417B - 模擬眼睛環境之裝置及方法 - Google Patents
模擬眼睛環境之裝置及方法 Download PDFInfo
- Publication number
- TWI460417B TWI460417B TW096140679A TW96140679A TWI460417B TW I460417 B TWI460417 B TW I460417B TW 096140679 A TW096140679 A TW 096140679A TW 96140679 A TW96140679 A TW 96140679A TW I460417 B TWI460417 B TW I460417B
- Authority
- TW
- Taiwan
- Prior art keywords
- test surface
- male
- concave
- female
- convex
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 33
- 238000012360 testing method Methods 0.000 claims description 169
- 239000011148 porous material Substances 0.000 claims description 22
- -1 Bisfi Afilcon A Chemical compound 0.000 claims description 20
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 13
- 238000012544 monitoring process Methods 0.000 claims description 9
- MMWFQFGXFPTUIF-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one 2-hydroxyethyl 2-methylprop-2-enoate 2-(2-methylprop-2-enoyloxy)ethyl 2-methylprop-2-enoate prop-2-enyl 2-methylprop-2-enoate Chemical compound C=CN1CCCC1=O.CC(=C)C(=O)OCCO.CC(=C)C(=O)OCC=C.CC(=C)C(=O)OCCOC(=O)C(C)=C MMWFQFGXFPTUIF-UHFFFAOYSA-N 0.000 claims description 6
- UURVHRGPGCBHIC-UHFFFAOYSA-N 3-(ethenoxycarbonylamino)propanoic acid 4-[[[[[[[[[[[[[[[[[[[[[[[[[[[4-ethenoxycarbonyloxybutyl(dimethyl)silyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]butyl ethenyl carbonate 1-ethenylpyrrolidin-2-one ethenyl N-[3-tris(trimethylsilyloxy)silylpropyl]carbamate Chemical compound C=CN1CCCC1=O.OC(=O)CCNC(=O)OC=C.C[Si](C)(C)O[Si](CCCNC(=O)OC=C)(O[Si](C)(C)C)O[Si](C)(C)C.C[Si](C)(CCCCOC(=O)OC=C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)CCCCOC(=O)OC=C UURVHRGPGCBHIC-UHFFFAOYSA-N 0.000 claims description 4
- 229920001616 Polymacon Polymers 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- NLAIHECABDOZBR-UHFFFAOYSA-M sodium 2,2-bis(2-methylprop-2-enoyloxymethyl)butyl 2-methylprop-2-enoate 2-hydroxyethyl 2-methylprop-2-enoate 2-methylprop-2-enoate Chemical compound [Na+].CC(=C)C([O-])=O.CC(=C)C(=O)OCCO.CCC(COC(=O)C(C)=C)(COC(=O)C(C)=C)COC(=O)C(C)=C NLAIHECABDOZBR-UHFFFAOYSA-M 0.000 claims description 4
- GNTAAQBKCCJXGF-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one methyl 2-methylprop-2-enoate 2-(2-methylprop-2-enoyloxy)ethyl 2-methylprop-2-enoate prop-2-enyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.C=CN1CCCC1=O.CC(=C)C(=O)OCC=C.CC(=C)C(=O)OCCOC(=O)C(C)=C GNTAAQBKCCJXGF-UHFFFAOYSA-N 0.000 claims description 3
- SVKHOOHZPMBIGM-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;2-hydroxyethyl 2-methylprop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.C=CN1CCCC1=O.CC(=C)C(=O)OCCO SVKHOOHZPMBIGM-UHFFFAOYSA-N 0.000 claims description 3
- XPSXBEJFSQZTBS-UHFFFAOYSA-N 2,2-bis(2-methylprop-2-enoyloxymethyl)butyl 2-methylprop-2-enoate 2-hydroxyethyl 2-methylprop-2-enoate N-(2-methyl-4-oxopentan-2-yl)prop-2-enamide Chemical compound CC(=C)C(=O)OCCO.CC(=O)CC(C)(C)NC(=O)C=C.CCC(COC(=O)C(C)=C)(COC(=O)C(C)=C)COC(=O)C(C)=C XPSXBEJFSQZTBS-UHFFFAOYSA-N 0.000 claims description 3
- KKOWZRLUUCIGQY-UHFFFAOYSA-N 2-hydroxyethyl 2-methylprop-2-enoate 2-methylprop-2-enoic acid 2-(2-methylprop-2-enoyloxy)ethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(O)=O.CC(=C)C(=O)OCCO.CC(=C)C(=O)OCCOC(=O)C(C)=C KKOWZRLUUCIGQY-UHFFFAOYSA-N 0.000 claims description 3
- PVISMVGVPWOQMG-UHFFFAOYSA-N 2-hydroxyethyl 2-methylprop-2-enoate;2-(2-methylprop-2-enoyloxy)ethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCO.CC(=C)C(=O)OCCOC(=O)C(C)=C PVISMVGVPWOQMG-UHFFFAOYSA-N 0.000 claims description 3
- 238000010998 test method Methods 0.000 claims description 2
- 239000011800 void material Substances 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 claims 1
- 239000000779 smoke Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 description 31
- 150000001875 compounds Chemical class 0.000 description 9
- 239000000203 mixture Substances 0.000 description 6
- 235000002639 sodium chloride Nutrition 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229960004958 ketotifen Drugs 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- SFOVDSLXFUGAIV-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]-n-piperidin-4-ylbenzimidazol-2-amine Chemical compound C1=CC(F)=CC=C1CN1C2=CC=CC=C2N=C1NC1CCNCC1 SFOVDSLXFUGAIV-UHFFFAOYSA-N 0.000 description 2
- ZKLPARSLTMPFCP-OAQYLSRUSA-N 2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic acid Chemical compound C1CN(CCOCC(=O)O)CCN1[C@@H](C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-OAQYLSRUSA-N 0.000 description 2
- QSAVEGSLJISCDF-UHFFFAOYSA-N 2-hydroxy-2-phenylacetic acid (1,2,2,6-tetramethyl-4-piperidinyl) ester Chemical compound C1C(C)(C)N(C)C(C)CC1OC(=O)C(O)C1=CC=CC=C1 QSAVEGSLJISCDF-UHFFFAOYSA-N 0.000 description 2
- USCSJAIWXWYTEH-UHFFFAOYSA-N 7-[3-[4-[(4-chlorophenyl)methyl]piperazin-1-yl]propoxy]-3,4-dimethylchromen-2-one Chemical compound C1=CC=2C(C)=C(C)C(=O)OC=2C=C1OCCCN(CC1)CCN1CC1=CC=C(Cl)C=C1 USCSJAIWXWYTEH-UHFFFAOYSA-N 0.000 description 2
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 2
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 2
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 2
- HOKDBMAJZXIPGC-UHFFFAOYSA-N Mequitazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1CC1C(CC2)CCN2C1 HOKDBMAJZXIPGC-UHFFFAOYSA-N 0.000 description 2
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 2
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 2
- DYAHQFWOVKZOOW-UHFFFAOYSA-N Sarin Chemical compound CC(C)OP(C)(F)=O DYAHQFWOVKZOOW-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229960002469 antazoline Drugs 0.000 description 2
- REYFJDPCWQRWAA-UHFFFAOYSA-N antazoline Chemical compound N=1CCNC=1CN(C=1C=CC=CC=1)CC1=CC=CC=C1 REYFJDPCWQRWAA-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 2
- 229940120638 avastin Drugs 0.000 description 2
- 229960002881 clemastine Drugs 0.000 description 2
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 2
- 229960001140 cyproheptadine Drugs 0.000 description 2
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 229960001971 ebastine Drugs 0.000 description 2
- MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 229950002420 eucatropine Drugs 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 229960003592 fexofenadine Drugs 0.000 description 2
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 229960000930 hydroxyzine Drugs 0.000 description 2
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 229960003630 ketotifen fumarate Drugs 0.000 description 2
- YNQQEYBLVYAWNX-WLHGVMLRSA-N ketotifen fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 YNQQEYBLVYAWNX-WLHGVMLRSA-N 0.000 description 2
- 229960001120 levocabastine Drugs 0.000 description 2
- ZCGOMHNNNFPNMX-KYTRFIICSA-N levocabastine Chemical compound C1([C@@]2(C(O)=O)CCN(C[C@H]2C)[C@@H]2CC[C@@](CC2)(C#N)C=2C=CC(F)=CC=2)=CC=CC=C1 ZCGOMHNNNFPNMX-KYTRFIICSA-N 0.000 description 2
- 229960001508 levocetirizine Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229960001474 meclozine Drugs 0.000 description 2
- 229960005042 mequitazine Drugs 0.000 description 2
- 229960001869 methapyrilene Drugs 0.000 description 2
- HNJJXZKZRAWDPF-UHFFFAOYSA-N methapyrilene Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CS1 HNJJXZKZRAWDPF-UHFFFAOYSA-N 0.000 description 2
- 229960004056 methdilazine Drugs 0.000 description 2
- HTMIBDQKFHUPSX-UHFFFAOYSA-N methdilazine Chemical compound C1N(C)CCC1CN1C2=CC=CC=C2SC2=CC=CC=C21 HTMIBDQKFHUPSX-UHFFFAOYSA-N 0.000 description 2
- 239000002637 mydriatic agent Substances 0.000 description 2
- 230000002911 mydriatic effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229960001528 oxymetazoline Drugs 0.000 description 2
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 2
- 229960001697 physostigmine Drugs 0.000 description 2
- 229950010674 picumast Drugs 0.000 description 2
- 229960003910 promethazine Drugs 0.000 description 2
- 229960002646 scopolamine Drugs 0.000 description 2
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 229960000351 terfenadine Drugs 0.000 description 2
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 2
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- WSSSPWUEQFSQQG-UHFFFAOYSA-N 4-methyl-1-pentene Chemical compound CC(C)CC=C WSSSPWUEQFSQQG-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 239000004812 Fluorinated ethylene propylene Substances 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 1
- IJHNSHDBIRRJRN-UHFFFAOYSA-N N,N-dimethyl-3-phenyl-3-(2-pyridinyl)-1-propanamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=CC=C1 IJHNSHDBIRRJRN-UHFFFAOYSA-N 0.000 description 1
- 229930182556 Polyacetal Natural products 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- ZZHLYYDVIOPZBE-UHFFFAOYSA-N Trimeprazine Chemical compound C1=CC=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1 ZZHLYYDVIOPZBE-UHFFFAOYSA-N 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- 229960003790 alimemazine Drugs 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 229960001803 cetirizine Drugs 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- HQQADJVZYDDRJT-UHFFFAOYSA-N ethene;prop-1-ene Chemical group C=C.CC=C HQQADJVZYDDRJT-UHFFFAOYSA-N 0.000 description 1
- 229920001038 ethylene copolymer Polymers 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000004095 hydrolyase inhibitor Substances 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 229960002422 lomefloxacin Drugs 0.000 description 1
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 229960002409 mepivacaine Drugs 0.000 description 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
- 229960003955 mianserin Drugs 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 1
- 229940033080 omega-6 fatty acid Drugs 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 229940054534 ophthalmic solution Drugs 0.000 description 1
- 229920009441 perflouroethylene propylene Polymers 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003856 thermoforming Methods 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000012815 thermoplastic material Substances 0.000 description 1
- 229920002397 thermoplastic olefin Polymers 0.000 description 1
- 229920005992 thermoplastic resin Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N13/00—Investigating surface or boundary effects, e.g. wetting power; Investigating diffusion effects; Analysing materials by determining surface, boundary, or diffusion effects
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01M—TESTING STATIC OR DYNAMIC BALANCE OF MACHINES OR STRUCTURES; TESTING OF STRUCTURES OR APPARATUS, NOT OTHERWISE PROVIDED FOR
- G01M11/00—Testing of optical apparatus; Testing structures by optical methods not otherwise provided for
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/02—Investigating particle size or size distribution
-
- G—PHYSICS
- G02—OPTICS
- G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
- G02C7/00—Optical parts
- G02C7/02—Lenses; Lens systems ; Methods of designing lenses
- G02C7/04—Contact lenses for the eyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N13/00—Investigating surface or boundary effects, e.g. wetting power; Investigating diffusion effects; Analysing materials by determining surface, boundary, or diffusion effects
- G01N2013/006—Dissolution of tablets or the like
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/44—Resins; Plastics; Rubber; Leather
- G01N33/442—Resins; Plastics
Landscapes
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Dispersion Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Eyeglasses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Eye Examination Apparatus (AREA)
- Materials For Medical Uses (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Instructional Devices (AREA)
- Prostheses (AREA)
Description
本發明關於模擬眼睛環境以利眼科鏡片測試的裝置及方法。
大多數眼睛疾病係用含有藥劑之局部眼科溶液治療。頃已認定如果將此等劑物納入眼科鏡片中並且利用此等鏡片當作投藥裝置，則此等劑物之投送和效力會大幅提昇。此等劑物可藉由多樣方法添加於眼科鏡片，其中包含使劑物滲入一已成型鏡片內、在鏡片成型之前將劑物添加於鏡片之調配物、及類似方法。他人已提出測試此等藥劑往返於眼科鏡片之攝入率和釋出率的方法。此等方法包含將眼科鏡片置入溶液內並監測藥劑之時間濃度變化。即便這些方法可行，因為測試中使用之溶液體積，測試條件並不像眼科鏡片在嵌入一眼睛環境中時所遭遇之條件。
在眼睛環境中，非常少量的淚液會在鏡片使用期間通過鏡片。因此，最好可以模仿這些條件來測試眼科鏡片之表現。本發明滿足此需求。
本發明包含一種用於測試一眼科鏡片的裝置，其包括一公模和一母模，其中該公模包括一凸形測試表面、一公外表面、從該
凸形測試表面之周圍伸出的公支承脊部、及一從該公外表面延伸至該凸形測試表面的孔隙，其中該母模包括一母外表面、一凹形測試表面、從該凹形測試表面之周圍伸出的母支承脊部、及一從該凹形測試表面延伸至該母外表面的孔隙，其中當該公模與該母模組合時，該公支承脊部安頓在該母支承脊部上且在該公凸形測試表面與該母凹形測試表面之間形成一測試區。
本發明之一實施例例示於下述圖式中。
圖1是一公模100的立體圖，其含有凸形測試表面120、孔隙160及公支承脊部180。圖2是一母模200的立體圖，其含有凹形測試表面220、孔隙260及母支承脊部280。圖3是一組合裝置之剖面放大圖，其中組合的凸形測試表面120和凹形測試表面220在這些表面之間界定測試區300。較佳來說，凸形和凹形測試表面具有模仿眼睛和眼瞼之形狀的大小和形狀。測試區300大到足以留住一眼科鏡片(圖中未示)及一份溶液。較佳來說，測試區經訂定大小以容納一眼科鏡片及約50微升至約500微升之溶液、更佳約100微升至約400微升之溶液、最佳約200微升之溶液。
裝置之凸形或凹形測試表面可含有提供讓少量溶液通過測試區所含眼科鏡片之表面之通路的溝槽。此等溝槽可
採取任意多樣取向，但較佳一凸形或凹形測試表面含有至少一緯度向溝槽及一徑向溝槽。較佳來說此等溝槽在凸形或凹形測試表面上之一點交會。在後續圖式所示之本發明一實施例中，凹形和凸形表面均含有徑向及緯度向溝槽。
圖4是一公模10之立體圖，其含有凸形測試表面12、四個徑向溝槽14、孔隙16、公支承脊部18、及六個同心緯度向溝槽19。圖5是一母模20之立體圖，其含有凹形測試表面22、四個徑向溝槽14、孔隙26、母支承脊部28、及九個同心緯度向溝槽29。凸形測試表面上的徑向溝槽與緯度向溝槽交會以便允許流過孔隙之溶液更容易流到整個凸形測試表面。這種結構排列也存在於凹形測試表面上。每一測試表面可含有相同或不同數量的徑向溝槽。較佳來說每一測試表面含有至少二個徑向溝槽、更佳三個徑向溝槽、最佳四個徑向溝槽。關於緯度向溝槽，每一測試表面上之此種溝槽的數量可為相同或不同。較佳來說每一測試表面含有至少四個緯度向溝槽、更佳至少五個緯度向溝槽、最佳至少八個緯度向溝槽。公和母外表面可具有相同或不同形狀。在本發明之一實施例(圖中未示)中，公外表面為凹形且母外表面為凸形。較佳來說，凸形和凹形測試表面具有模仿眼睛和眼瞼之形狀的大小和形狀。
圖6是一組合裝置的剖面圖，其具備公模10、母模20、公外表面13、母外表面23、公支承脊部18、及母支承脊部28。如圖6所示，孔隙16從公外表面13延伸穿過凸形測試表面12到圖中未示的測試區。又，孔隙26從凹形測
試表面22延伸至母外表面23。圖7是一組合裝置的剖面放大圖，其中已組合的凸形測試表面12和凹形測試表面22於其間界定測試區30。測試區30大到足以留住一眼科鏡片(圖中未示)及一份溶液。較佳來說測試區經訂定大小以容納一眼科鏡片及約50微升至約500微升之溶液、更佳約100微升至約400微升之溶液、最佳約200微升之溶液。
本發明之裝置可由耐久的熱塑性材料製備，譬如熱塑性樹脂類、聚烯烴類、及熱塑性聚酯類。此等材料之實例非侷限性包含低密度、中密度和高密度聚丙烯、聚乙烯及以上之共聚物類，聚-4-甲基戊烯、氟化乙烯丙烯共聚物類、乙烯氟化乙烯共聚物類、聚縮醛樹脂類、聚丙烯醚、聚丙烯醚碸類、尼龍類、及類似物。裝置可藉由射出成型、熱成型及類似方法製備。
又，本發明包含一種測試一包括一藥劑之眼科器件之擴散率的方法，其中該方法包括以下步驟：(a)將一包括一藥劑的眼科鏡片放入一裝置之測試區內，該裝置包括一公模和一母模，其中該公模包括一凸形測試表面、一公外表面、從該凸形測試表面之周圍伸出的公支承脊部、及一從該公外表面延伸至該凸形測試表面的孔隙，其中該母模包括一母外表面、一凹形測試表面、從該凹形測試表面之周圍伸出的母支承脊部、及一從該凹形測試表面延伸至該母外表面的孔隙，
其中當該公模與該母模組合時，該公支承脊部安頓在該母支承脊部上且在該公凸形測試表面與該母凹形測試表面之間形成一測試區。
(b)從該公外表面將一溶液添加至該公模之孔隙，且(c)監測從該母外表面之孔隙冒出的該溶液以判斷該藥劑之存在或不存在。
此處所述公模、母模、徑向溝槽、緯度向溝槽、測試區、凸形測試表面、及凹形測試表面均如前所述。
在本說明書中，〝藥劑〞一辭係指用來治療眼睛之症狀的藥學或營養學化合物，且此化合物會在有氧及某些過渡金屬存在的情況下劣化。藥學化合物之實例包含抗組織胺類、抗生素類、抗菌劑類、抗病毒劑類、抗黴菌劑類、止痛劑類、麻醉劑類、抗過敏劑類、肥胖細胞穩定劑類、類固醇和非類固醇抗炎劑類、血管新生抑制劑類；抗代謝物類、纖維蛋白分解物類、神經保護藥類、血管生成類固醇類、散瞳劑類、睫狀肌鬆弛(cyclopegic)散瞳劑類；縮瞳劑類；血管緊縮劑類；血管擴張劑類、抗凝血劑類；抗癌劑類、反義(antisense)劑類、免疫調節劑類、碳酸脫水酶抑制劑類、integrin antabonistsl；環氧酶抑制劑類、VEGF拮抗劑類；免疫作用抑制劑類及類似物。特定言之，藥學化合物之實例非侷限性包含阿伐斯汀、安他唑啉、阿司咪唑、阿扎他定、氮斯汀、布克利嗪、布比卡因、西替利嗪、氯馬斯汀、賽克力嗪、賽庚啶、ebastine、依米達斯汀、麻黃鹼、尤卡托品、fexofenadine、后馬托品、羥嗪、酮替
芬、左卡巴斯汀、左西替利嗪、洛美沙星、美其敏、甲哌卡因、美喹他嗪、methdilazine、methapyrilene、米安色林、萘甲唑啉、norastemizole、norebsatine、氧氟沙星、羥甲唑啉、非尼拉敏、去氧腎上腺素、毒扁豆鹼、picumast、異丙嗪、東莨菪鹼、特非那定、tetrahydozoline、硫乙拉嗪、噻嗎洛爾、甲基丙嗪、曲普利定、藥學可接受的鹽類暨以上之混合物。較佳的藥學化合物包含阿伐斯汀、安他唑啉、阿司咪唑、阿扎他定、氮斯汀、氯馬斯汀、賽庚啶、ebastine、依米達斯汀、尤卡托品、fexofenadine、后馬托品、羥嗪、酮替芬、左卡巴斯汀、左西替利嗪、美其敏、美喹他嗪、methdilazine、methapyrilene、norastemizole、norebsatine、羥甲唑啉、毒扁豆鹼、picumast、異丙嗪、東莨菪鹼、特非那定、tetrahyerozoline、fimilol、甲基丙嗪、曲普利定、藥學可接受的鹽類暨以上之混合物。特佳的藥學化合物包含phenarimine、酮替芬、富馬酸酮替芬、11-二羥基-11-(1-甲基-4-亞哌啶基)-5H-咪唑[2,1-b][3]benzazepine-羧醛(CAS# 147084-10-4)、olapatadine暨以上之混合物。更特別好的藥學化合物包含富馬酸酮替芬、11-二羥基-11-(1-甲基-4-亞哌啶基)-5H-咪唑[2,1-b][3]benzazepine-羧醛(CAS# 147084-10-4)暨以上之混合物。
營養學化合物之實例包含維他命及補品，譬如維他命A、D、E，黃體素，玉米黃質，硫辛酸，類黃酮，與眼睛相容的脂肪酸譬如Ω3和Ω6脂肪酸，以上之組合、與藥學
化合物之組合及類似物。本發明之方法可用於偵測含有約8微克或更多藥劑之眼科鏡片之釋出率(或攝入率)。較佳來說，可藉由本發明之方法判斷含有約8微克至約90微克、更佳約10微克至約40微克、更佳約10微克至約25微克之眼科鏡片的釋出率。
在本說明書中，〝眼科鏡片〞意指放在眼上或眼中的任何器件。此等器件可提供光學矯正效果或者可為裝飾性。眼科鏡片非侷限性包含軟式隱形眼鏡、眼內鏡片、疊蓋鏡片、眼球嵌件、及光學嵌件。本發明之較佳鏡片是由聚矽氧彈性體類或水凝膠類製成的軟式隱形眼鏡，此等材料非侷限性包含聚矽氧水凝膠類及氟水凝膠類。軟式隱形眼鏡調配物揭示於美國專利第5,710,302號、WO 9421698號、EP 406161號、JP 2000016905號、美國專利第5,998,498號、美國專利第6,087,415號、美國專利第5,760,100號、美國專利第5,776,999號、美國專利第5,789,461號、美國專利第5,849,811號、及美國專利第5,965,631號。以上各專利之完整內容以引用的方式併入本發明中。本發明之特佳眼科鏡片為下列美國國家核定名稱(United States Approved Names)者：acofilcon A，alofilcon A，alphafilcon A，amifilcon A，astifilcon A，atalafilcon A，balafilcon A，bisfilcon A，bufilcon A，comfilcon，crofilcon A，cyclofilcon A，darfilcon A，deltafilcon A，deltafilcon B，dimefilcon A，drooxifilcon A，epsifilcon A，esterifilcon A，etafilcon A，focofilcon A，genfilcon A，govafilcon A，hefilcon A，
hefilcon B，hefilcon D，hilafilcon A，hilafilcon B，hioxifilcon B，hioxifilcon C，hixoifilcon A，hydrofilcon A，lenefilcon A，licryfilcon A，licryfilcon B，lidofilcon A，lidofilcon B，lotrafilcon A，lotrafilcon B，mafilcon A，mesifilcon A，methafilcon B，mipafilcon A，nelfilcon A，netrafilcon A，ocufilcon A，ocufilcon B，ocufilcon C，ocufilcon D，ocufilcon E，ofilcon A，omafilcon A，oxyfilcon A，pentafilcon A，perfilcon A，pevafilcon A，phemfilcon A，polymacon，silafilcon A，siloxyfilcon A，tefilcon A，tetrafilcon A，trifilcon A，vifilcon，及xylofilcon A。更特別好的本發明眼科鏡片為genfilcon A，lenefilcon A，comfilcon，lotrafilcon A，lotrafilcon B，及balafilcon A。最佳的鏡片包含etafilcon A，nelfilcon A，hilafilcon，vifilcon，及polymacon。
本發明之方法中使用的〝溶液〞可為水基溶液。較佳為模仿自然淚膜的溶液。典型的溶液非侷限性包含沙林溶液類、其他緩衝溶液、及去離子水。較佳的水溶液是去離子水或是含有下列鹽類之沙林溶液：氯化鈉、硼酸鈉、磷酸鈉、磷酸氫二鈉、磷酸二氫鈉、或上述鹽類之對應鉀鹽類。這些成份通常經組合以形成包含一種酸及其共軛鹼的緩衝溶液，使得酸和鹼之添加只會導致pH值相對小幅變化。緩衝溶液可能額外包含2-(N-嗎啉)乙磺酸(MES)，氫氧化鈉，2,2-雙(羥甲基)-2,2',2"-氮三乙醇，n-三(羥甲基)甲基-2-胺乙磺酸，檸檬酸，檸檬酸鈉，碳酸鈉，碳酸氫鈉，
乙酸，乙酸鈉，乙二胺四乙酸及以上之類似物和組合。
在本說明書中，〝監測〞係指分析溶液以判定溶液中之藥劑濃度的方法。此等偵測方法之實例非侷限性包含HPLC、UV光度測定及類似方法。
另外，本發明包含一種測量一眼科鏡片之一藥劑攝入率的方法，其中該方法包括以下步驟：(a)將一眼科鏡片放入一裝置之測試區內，該裝置包括一公模和一母模，其中該公模包括一凸形測試表面、一公外表面、從該凸形測試表面之周圍伸出的公支承脊部、及一從該公外表面延伸至該凸形測試表面的孔隙，其中該母模包括一母外表面、一凹形測試表面、從該凹形測試表面之周圍伸出的母支承脊部、及一從該凹形測試表面延伸至該母外表面的孔隙，其中當該公模與該母模組合時，該公支承脊部安頓在該母支承脊部上且在該公凸形測試表面與該母凹形測試表面之間形成一測試區。
(b)從該公外表面將一包括一藥劑的溶液添加至該公模之孔隙，且(c)監測從該母外表面之孔隙冒出的該溶液以判斷該藥劑之存在或不存在。
此處所述公模、母模、徑向溝槽、緯度向溝槽、測試區、凸形測試表面、凹形測試表面、藥劑、眼科鏡片、溶液及監測均如前所述。
還有一些情況是吾人想要測試一眼科鏡片在一眼睛環境中之表現，不是該眼科鏡片含有一藥劑時之情況。舉例來說，如果吾人想要判斷是否有界面活性劑類、賦形劑類、防腐劑類、潤濕劑類或其他溶劑組份(〝眼睛保健溶液組份〞)被鏡片吸收，最好有一測試模仿鏡片在一眼睛環境中之表現。鑑於此需求，本發明包含一種測量一眼科鏡片之一眼睛保健溶液組份攝入率的方法，其中該方法包括以下步驟：(a)將一眼科鏡片放入一裝置之測試區內，該裝置包括一公模和一母模，其中該公模包括一凸形測試表面、一公外表面、從該凸形測試表面之周圍伸出的公支承脊部、及一從該公外表面延伸至該凸形測試表面的孔隙，其中該母模包括一母外表面、一凹形測試表面、從該凹形測試表面之周圍伸出的母支承脊部、及一從該凹形測試表面延伸至該母外表面的孔隙，其中當該公模與該母模組合時，該公支承脊部安頓在該母支承脊部上且在該公凸形測試表面與該母凹形測試表面之間形成一測試區。
(b)從該公外表面將一包括一眼睛保健溶液組份的溶液添加至該公模之孔隙，且(c)監測從該母外表面之孔隙冒出的該溶液以判斷該眼睛保健溶液組份之存在或不存在。
此處所述公模、母模、徑向溝槽、緯度向溝槽、測試
區、凸形測試表面、凹形測試表面、眼睛保健溶液組份、眼科鏡片、溶液及監測均如前所述。
以上舉例說明本發明之裝置及方法的指定實施例，但不限制本發明。其僅為建議一種施行本發明之方法。熟悉隱形眼鏡之人及其他專家可找出施行本發明之其他方法。但這些方法會被視為是在本發明之範圍以內。
10‧‧‧公模
12‧‧‧凸形測試表面
13‧‧‧公外表面
14‧‧‧徑向溝槽
16‧‧‧孔隙
18‧‧‧公支承脊部
19‧‧‧同心緯度向溝槽
20‧‧‧母模
22‧‧‧凹形測試表面
23‧‧‧母外表面
24‧‧‧徑向溝槽
26‧‧‧孔隙
28‧‧‧母支承脊部
29‧‧‧同心緯度向溝槽
30‧‧‧測試區
100‧‧‧公模
120‧‧‧凸形測試表面
160‧‧‧孔隙
180‧‧‧公支承脊部
200‧‧‧母模
220‧‧‧凹形測試表面
260‧‧‧孔隙
280‧‧‧母支承脊部
300‧‧‧測試區
圖1例示一公模之立體圖。
圖2例示一母模之立體圖。
圖3例示一組合裝置之剖面放大圖。
圖4例示一公模之立體圖。
圖5例示一母模之立體圖。
圖6例示一組合裝置之剖面圖。
圖7例示一組合裝置之剖面放大圖。
120‧‧‧凸形測試表面
160‧‧‧孔隙
220‧‧‧凹形測試表面
300‧‧‧測試區
Claims (22)
- 一種用於測試一眼科鏡片的裝置，其包括一公模和一母模，其中該公模包括一凸形測試表面、一公外表面、從該凸形測試表面之周圍伸出的公支承脊部、及一從該公外表面延伸至該凸形測試表面的孔隙，其中該母模包括一母外表面、一凹形測試表面、從該凹形測試表面之周圍伸出的母支承脊部、及一從該凹形測試表面延伸至該母外表面的孔隙，其中當該公模與該母模組合時，該公支承脊部安頓在該母支承脊部上且在該公凸形測試表面與該母凹形測試表面之間形成一測試區，其中該凸形測試表面包括至少一從該孔隙延伸至該凸形測試表面之周圍的徑向溝槽及至少一與該至少一徑向溝槽交會的緯度向溝槽。
- 如申請專利範圍第1項之裝置，其中該凸形測試表面包括至少二個徑向溝槽。
- 如申請專利範圍第1項之裝置，其中該凸形測試表面包括至少四個徑向溝槽。
- 如申請專利範圍第1項之裝置，其中該凸形測試表面包括至少二個緯度向溝槽。
- 如申請專利範圍第1項之裝置，其中該凹形測試表面包括至少一從該孔隙延伸至該凹形測試表面之周圍的徑向溝槽及至少一與該至少一徑向溝槽交會的緯度向溝 槽。
- 如申請專利範圍第5項之裝置，其中該凹形測試表面包括至少二個徑向溝槽。
- 如申請專利範圍第5項之裝置，其中該凹形測試表面包括至少四個緯度向溝槽。
- 如申請專利範圍第5項之裝置，其中該凹形測試表面包括至少四個徑向溝槽。
- 如申請專利範圍第1項之裝置，其中該凹形測試表面包括至少一從該孔隙延伸至該凹形測試表面之周圍的徑向溝槽及至少一與該至少一徑向溝槽交會的緯度向溝槽。
- 如申請專利範圍第9項之裝置，其中該凸形測試表面包括至少二個徑向溝槽及至少三個緯度向溝槽且該凹形表面包括至少二個徑向溝槽及至少三個緯度向溝槽。
- 一種測試一包括一藥劑之眼科器件之擴散率的方法，其中該方法包括以下步驟：(a)將一包括一藥劑的眼科鏡片放入一裝置之測試區內，該裝置包括一公模和一母模，其中該公模包括一凸形測試表面、一公外表面、從該凸形測試表面之周圍伸出的公支承脊部、及一從該公外表面延伸至該凸形測試表面的孔隙，其中該母模包括一母外表面、一凹形測試表面、從該凹形測試表面之周圍伸出的母支承脊部、及一從該凹形測試表面延伸至該母外表面的孔隙， 其中當該公模與該母模組合時，該公支承脊部安頓在該母支承脊部上且在該公凸形測試表面與該母凹形測試表面之間形成一測試區，其中該凸形測試表面包括至少一從該孔隙延伸至該凸形測試表面之周圍的徑向溝槽及至少一與該至少一徑向溝槽交會的緯度向溝槽，(b)從該公外表面將一溶液添加至該公模之孔隙，且(c)監測從該母外表面之孔隙冒出的該溶液以判斷該藥劑之存在或不存在。
- 如申請專利範圍第11項之方法，其中該眼科鏡片係從由下列物組成之群中選出：阿可菲康A(acofilcon A)，阿羅菲康A(alofilcon A)，阿爾發菲康A(alphafilcon A)，阿米菲康A(amifilcon A)，阿斯特菲康A(astifilcon A)，阿塔拉菲康A(atalafilcon A)，巴拉菲康A(balafilcon A)，必思菲康A(bisfilcon A)，布菲康A(bufilcon A)，抗菲康(comfilcon)，克羅菲康A(crofilcon A)，賽克羅菲康A(cyclofilcon A)，達爾菲康A(darfilcon A)，戴爾他菲康A(deltafilcon A)，戴爾他菲康B(deltafilcon B)，迪美菲康A(dimefilcon A)，德洛克斯菲康A(drooxifilcon A)，艾普斯菲康A(epsifilcon A)，艾斯特利菲康A(esterifilcon A)，艾他菲康A(etafilcon A)，佛克菲康A(focofilcon A)，健菲康A(genfilcon A)，芶瓦菲康A(govafilcon A)，荷菲康A(hefilcon A)，荷菲康B(hefilcon B)，荷菲康D(hefilcon D)，亥拉菲康 A(hilafilcon A)，亥拉菲康B(hilafilcon B)，亥歐克斯菲康B(hioxifilcon B)，亥歐克斯菲康C(hioxifilcon C)，亥克斯歐菲康A(hixoifilcon A)，亥卓菲康A(hydrofilcon A)，雷尼菲康A(lenefilcon A)，利克萊菲康A(licryfilcon A)，利克萊菲康B(licryfilcon B)，利荳菲康A(lidofilcon A)，利荳菲康B(lidofilcon B)，羅特萊菲康A(lotrafilcon A)，羅特拉菲康B(lotrafilcon B)，瑪菲康A(mafilcon A)，麥斯菲康A(mesifilcon A)，麥莎菲康B(methafilcon B)，米帕菲康A(mipafilcon A)，耐爾菲康A(nelfilcon A)，耐特拉菲康A(netrafilcon A)，歐庫菲康A(ocufilcon A)，歐庫菲康B(ocufilcon B)，歐庫菲康C(ocufilcon C)，歐庫菲康D(ocufilcon D)，歐庫菲康E(ocufilcon E)，歐菲康A(ofilcon A)，歐瑪菲康A(omafilcon A)，歐克斯菲康A(oxyfilcon A)，盆他菲康A(pentafilcon A)，波爾菲康A(perfilcon A)，波瓦菲康A(pevafilcon A)，菲姆菲康A(phemfilcon A)，波利馬康(polymacon)，席拉菲康A(silafilcon A)，席羅克斯菲康A(siloxyfilcon A)，太菲康A(tefilcon A)，太特拉菲康A(tetrafilcon A)，特端菲康A(trifilcon A)，於菲康(vifilcon)，及克斯羅菲康A(xylofilcon A)。
- 如申請專利範圍第11項之方法，其中該凹形測試表面包括至少一從該孔隙延伸至該凹形測試表面之周圍的徑向溝槽及至少一與該至少一徑向溝槽交會的緯度向溝槽。
- 如申請專利範圍第11項之方法，其中該凹形測試表面包括至少一從該孔隙延伸至該凹形測試表面之周圍的徑向溝槽及至少一與該至少一徑向溝槽交會的緯度向溝槽。
- 如申請專利範圍第14項之方法，其中該凸形測試表面包括至少二個徑向溝槽及至少三個緯度向溝槽且該凹形表面包括至少二個徑向溝槽及至少三個緯度向溝槽。
- 一種測試一眼科鏡片之一藥劑攝入率的方法，其中該方法包括以下步驟：(a)將一眼科鏡片放入一裝置之測試區內，該裝置包括一公模和一母模，其中該公模包括一凸形測試表面、一公外表面、從該凸形測試表面之周圍伸出的公支承脊部、及一從該公外表面延伸至該凸形測試表面的孔隙，其中該母模包括一母外表面、一凹形測試表面、從該凹形測試表面之周圍伸出的母支承脊部、及一從該凹形測試表面延伸至該母外表面的孔隙，其中當該公模與該母模組合時，該公支承脊部安頓在該母支承脊部上且在該公凸形測試表面與該母凹形測試表面之間形成一測試區，其中該凸形測試表面包括至少一從該孔隙延伸至該凸形測試表面之周圍的徑向溝槽及至少一與該至少一徑向溝槽交會的緯度向溝槽，(b)從該公外表面將一包括一藥劑的溶液添加至該公 模之孔隙，且(c)監測從該母外表面之孔隙冒出的該溶液以判斷該藥劑之存在或不存在。
- 如申請專利範圍第16項之方法，其中該眼科鏡片係從由下列物組成之群中選出：阿可菲康A(acofilcon A)，阿羅菲康A(alofilcon A)，阿爾發菲康A(alphafilcon A)，阿米菲康A(amifilcon A)，阿斯特菲康A(astifilcon A)，阿塔拉菲康A(atalafilcon A)，巴拉菲康A(balafilcon A)，必思菲康A(bisfilcon A)，布菲康A(bufilcon A)，抗菲康(comfilcon)，克羅菲康A(crofilcon A)，賽克羅菲康A(cyclofilcon A)，達爾菲康A(darfilcon A)，戴爾他菲康A(deltafilcon A)，戴爾他菲康B(deltafilcon B)，迪美菲康A(dimefilcon A)，德洛克斯菲康A(drooxifilcon A)，艾普斯菲康A(epsifilcon A)，艾斯特利菲康A(esterifilcon A)，艾他菲康A(etafilcon A)，佛克菲康A(focofilcon A)，健菲康A(genfilcon A)，芶瓦菲康A(govafilcon A)，荷菲康A(hefilcon A)，荷菲康B(hefilcon B)，荷菲康D(hefilcon D)，亥拉菲康A(hilafilcon A)，亥拉菲康B(hilafilcon B)，亥歐克斯菲康B(hioxifilcon B)，亥歐克斯菲康C(hioxifilcon C)，亥克斯歐菲康A(hixoifilcon A)，亥卓菲康A(hydrofilcon A)，雷尼菲康A(lenefilcon A)，利克萊菲康A(licryfilcon A)，利克萊菲康B(licryfilcon B)，利荳菲康A(lidofilcon A)，利荳菲康B(lidofilcon B)，羅 特萊菲康A(lotrafilcon A)，羅特拉菲康B(lotrafilcon B)，瑪菲康A(mafilcon A)，麥斯菲康A(mesifilcon A)，麥莎菲康B(methafilcon B)，米帕菲康A(mipafilcon A)，耐爾菲康A(nelfilcon A)，耐特拉菲康A(netrafilcon A)，歐庫菲康A(ocufilcon A)，歐庫菲康B(ocufilcon B)，歐庫菲康C(ocufilcon C)，歐庫菲康D(ocufilcon D)，歐庫菲康E(ocufilcon E)，歐菲康A(ofilcon A)，歐瑪菲康A(omafilcon A)，歐克斯菲康A(oxyfilcon A)，盆他菲康A(pentafilcon A)，波爾菲康A(perfilcon A)，波瓦菲康A(pevafilcon A)，菲姆菲康A(phemfilcon A)，波利馬康(polymacon)，席拉菲康A(silafilcon A)，席羅克斯菲康A(siloxyfilcon A)，太菲康A(tefilcon A)，太特拉菲康A(tetrafilcon A)，特瑞菲康A(trifilcon A)，於菲康(vifilcon)，及克斯羅菲康A(xylofilcon A)。
- 如申請專利範圍第16項之方法，其中該凹形測試表面包括至少一從該孔隙延伸至該凹形測試表面之周圍的徑向溝槽及至少一與該至少一徑向溝槽交會的緯度向溝槽。
- 如申請專利範圍第16項之方法，其中該凹形測試表面包括至少一從該孔隙延伸至該凹形測試表面之周圍的徑向溝槽及至少一與該至少一徑向溝槽交會的緯度向溝槽。
- 如申請專利範圍第19項之方法，其中該凸形測試表面包括至少二個徑向溝槽及至少三個緯度向溝槽且該凹 形表面包括至少二個徑向溝槽及至少三個緯度向溝槽。
- 一種測試一眼科鏡片之一眼睛保健溶液組份攝入率的方法，其中該方法包括以下步驟：(a)將一眼科鏡片放入一裝置之測試區內，該裝置包括一公模和一母模，其中該公模包括一凸形測試表面、一公外表面、從該凸形測試表面之周圍伸出的公支承脊部、及一從該公外表面延伸至該凸形測試表面的孔隙，其中該母模包括一母外表面、一凹形測試表面、從該凹形測試表面之周圍伸出的母支承脊部、及一從該凹形測試表面延伸至該母外表面的孔隙，其中當該公模與該母模組合時，該公支承脊部安頓在該母支承脊部上且在該公凸形測試表面與該母凹形測試表面之間形成一測試區，其中該凸形測試表面包括至少一從該孔隙延伸至該凸形測試表面之周圍的徑向溝槽及至少一與該至少一徑向溝槽交會的緯度向溝槽，(b)從該公外表面將一包括一眼睛保健溶液組份的溶液添加至該公模之孔隙，且(c)監測從該母外表面之孔隙冒出的該溶液以判斷該眼睛保健溶液組份之存在或不存在。
- 如申請專利範圍第21項之方法，其中該凹形測試表面包括至少一從該孔隙延伸至該凹形測試表面之周圍的徑向溝槽及至少一與該至少一徑向溝槽交會的緯度向 溝槽。
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85543306P | 2006-10-31 | 2006-10-31 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW200837342A TW200837342A (en) | 2008-09-16 |
| TWI460417B true TWI460417B (zh) | 2014-11-11 |
Family
ID=39154017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW096140679A TWI460417B (zh) | 2006-10-31 | 2007-10-30 | 模擬眼睛環境之裝置及方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7793535B2 (zh) |
| EP (1) | EP2078186B1 (zh) |
| JP (1) | JP2010508562A (zh) |
| KR (1) | KR20090094816A (zh) |
| CN (1) | CN101573604B (zh) |
| AR (1) | AR063753A1 (zh) |
| AU (1) | AU2007313797A1 (zh) |
| BR (1) | BRPI0718298A2 (zh) |
| CA (1) | CA2668296C (zh) |
| HK (2) | HK1133297A1 (zh) |
| RU (1) | RU2443999C2 (zh) |
| TW (1) | TWI460417B (zh) |
| WO (1) | WO2008055047A2 (zh) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2083793A2 (en) * | 2006-10-31 | 2009-08-05 | Johnson and Johnson Vision Care, Inc. | Methods and devices to test diffusion rates of ocular drug delivery systems |
| US7968018B2 (en) * | 2007-04-18 | 2011-06-28 | Coopervision International Holding Company, Lp | Use of surfactants in extraction procedures for silicone hydrogel ophthalmic lenses |
| US8295684B2 (en) * | 2007-10-08 | 2012-10-23 | Sony Computer Entertainment America Inc. | Method and system for scaling content for playback with variable duration |
| US9827250B2 (en) | 2012-07-31 | 2017-11-28 | Johnson & Johnson Vision Care, Inc. | Lens incorporating myopia control optics and muscarinic agents |
| US9069186B2 (en) * | 2013-03-15 | 2015-06-30 | Johnson & Johnson Vision Care, Inc. | Thermoformed ophthalmic insert devices |
| KR20200048825A (ko) * | 2018-10-30 | 2020-05-08 | 부산대학교 산학협력단 | 가상현실 기반의 백내장 수술 시뮬레이터 시스템 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5817924A (en) * | 1998-01-21 | 1998-10-06 | Modern Controls, Inc. | Method and apparatus for measuring oxygen transmission through contact lenses |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601967D0 (en) * | 1986-01-28 | 1986-03-05 | Coopervision Optics | Manufacturing contact lenses |
| US4782946A (en) * | 1987-09-17 | 1988-11-08 | Allergan, Inc. | Soft contact lens hydration device and kit |
| US5115056A (en) | 1989-06-20 | 1992-05-19 | Ciba-Geigy Corporation | Fluorine and/or silicone containing poly(alkylene-oxide)-block copolymers and contact lenses thereof |
| US5374662A (en) | 1993-03-15 | 1994-12-20 | Bausch & Lomb Incorporated | Fumarate and fumaramide siloxane hydrogel compositions |
| TW325744U (en) * | 1993-07-21 | 1998-01-21 | Ciba Geigy Ag | Two-sided contact lens mold |
| US5490415A (en) * | 1994-04-15 | 1996-02-13 | Pharmetrix Corporation | Diffusion test apparatus and method |
| US5760100B1 (en) | 1994-09-06 | 2000-11-14 | Ciba Vision Corp | Extended wear ophthalmic lens |
| TW585882B (en) | 1995-04-04 | 2004-05-01 | Novartis Ag | A method of using a contact lens as an extended wear lens and a method of screening an ophthalmic lens for utility as an extended-wear lens |
| CN1084335C (zh) | 1995-12-07 | 2002-05-08 | 博士伦公司 | 用于降低硅氧烷水凝胶的模量的单体单元 |
| JP3813667B2 (ja) | 1996-09-24 | 2006-08-23 | 株式会社トーメー | コンタクトレンズ用洗浄・消毒用具及びそれを用いたコンタクトレンズの消毒方法 |
| US5998498A (en) | 1998-03-02 | 1999-12-07 | Johnson & Johnson Vision Products, Inc. | Soft contact lenses |
| US6087415A (en) | 1998-06-11 | 2000-07-11 | Johnson & Johnson Vision Care, Inc. | Biomedical devices with hydrophilic coatings |
| JP2000016905A (ja) | 1998-07-01 | 2000-01-18 | Tokuriki Kagaku Kenkyusho:Kk | 抗菌抗かび剤および抗菌抗かび材料 |
| US6450014B1 (en) * | 1999-12-28 | 2002-09-17 | Eastman Kodak Company | Method and apparatus for measuring osmotic pressure |
| ATE310634T1 (de) * | 2001-05-23 | 2005-12-15 | Novartis Pharma Gmbh | Aufnahmekorb für eine ophtalmische linse |
| US6909503B2 (en) * | 2001-08-17 | 2005-06-21 | Novartis Ag | Cuvette for lens inspection |
| DE60326597D1 (de) | 2002-06-05 | 2009-04-23 | Univ Florida | Ophthalmisches arzneimittelabgabesystem |
| US6981403B2 (en) * | 2003-10-31 | 2006-01-03 | Mocon, Inc. | Method and apparatus for measuring gas transmission rates of deformable or brittle materials |
| CA2597219C (en) * | 2005-02-04 | 2014-04-15 | Auburn University | Contact drug delivery system |
| SG177132A1 (en) * | 2005-02-14 | 2012-01-30 | Johnson & Johnson Vision Care | A comfortable ophthalmic device and methods of its production |
| EP2083793A2 (en) * | 2006-10-31 | 2009-08-05 | Johnson and Johnson Vision Care, Inc. | Methods and devices to test diffusion rates of ocular drug delivery systems |
-
2007
- 2007-10-25 US US11/923,680 patent/US7793535B2/en active Active
- 2007-10-26 WO PCT/US2007/082584 patent/WO2008055047A2/en active Application Filing
- 2007-10-26 BR BRPI0718298-8A patent/BRPI0718298A2/pt not_active IP Right Cessation
- 2007-10-26 EP EP07854430.1A patent/EP2078186B1/en not_active Not-in-force
- 2007-10-26 CA CA2668296A patent/CA2668296C/en not_active Expired - Fee Related
- 2007-10-26 KR KR1020097011210A patent/KR20090094816A/ko not_active Application Discontinuation
- 2007-10-26 RU RU2009120559/28A patent/RU2443999C2/ru not_active IP Right Cessation
- 2007-10-26 AU AU2007313797A patent/AU2007313797A1/en not_active Abandoned
- 2007-10-26 JP JP2009535401A patent/JP2010508562A/ja active Pending
- 2007-10-26 CN CN2007800489590A patent/CN101573604B/zh not_active Expired - Fee Related
- 2007-10-30 TW TW096140679A patent/TWI460417B/zh active
- 2007-10-31 AR ARP070104839A patent/AR063753A1/es not_active Application Discontinuation
-
2009
- 2009-11-25 HK HK09111019.5A patent/HK1133297A1/zh not_active IP Right Cessation
-
2010
- 2010-05-03 HK HK10104340.7A patent/HK1138640A1/zh not_active IP Right Cessation
- 2010-08-05 US US12/851,434 patent/US20100300182A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5817924A (en) * | 1998-01-21 | 1998-10-06 | Modern Controls, Inc. | Method and apparatus for measuring oxygen transmission through contact lenses |
Non-Patent Citations (1)
| Title |
|---|
| C.C.S. Karlgard et al., "In vitro uptake and release studies of ocular pharmaceutical agents by silicon-containing and p-HEMA hydrogel contact lens materials", International Journal of Pharmaceutics, Vol. 257, pp. 141–151, 2003 * |
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0718298A2 (pt) | 2013-12-03 |
| KR20090094816A (ko) | 2009-09-08 |
| TW200837342A (en) | 2008-09-16 |
| HK1138640A1 (zh) | 2010-08-27 |
| AR063753A1 (es) | 2009-02-18 |
| US7793535B2 (en) | 2010-09-14 |
| US20100300182A1 (en) | 2010-12-02 |
| EP2078186B1 (en) | 2014-05-07 |
| RU2009120559A (ru) | 2010-12-10 |
| CA2668296C (en) | 2015-12-29 |
| CN101573604B (zh) | 2013-12-04 |
| CA2668296A1 (en) | 2008-05-08 |
| RU2443999C2 (ru) | 2012-02-27 |
| HK1133297A1 (zh) | 2010-03-19 |
| WO2008055047A2 (en) | 2008-05-08 |
| EP2078186A2 (en) | 2009-07-15 |
| CN101573604A (zh) | 2009-11-04 |
| AU2007313797A1 (en) | 2008-05-08 |
| JP2010508562A (ja) | 2010-03-18 |
| WO2008055047A3 (en) | 2008-06-26 |
| US20080100795A1 (en) | 2008-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI460417B (zh) | 模擬眼睛環境之裝置及方法 | |
| US20240142666A1 (en) | Comfortable ophthalmic device and methods of its production | |
| TWI424844B (zh) | 用於治療眼睛過敏之方法及眼用裝置 | |
| CN108463323A (zh) | 带腔可调节透镜 | |
| Pereira-da-Mota et al. | Testing drug release from medicated contact lenses: The missing link to predict in vivo performance | |
| CN110650734A (zh) | 治疗与隐形眼镜有关病症的包含半氟化烷烃的药物组合物 | |
| CN101573102B (zh) | 测试眼部药物递送系统扩散率的方法和装置 | |
| TWI651095B (zh) | 具有抗敏舒緩效果的眼用產品 | |
| Laddha et al. | Development, optimization and enhancement of transcorneal permeation of Timolol Maleate from a novel in situ gel | |
| Patel et al. | Formulation and In Vitro Evaluation of Gatifloxacin Ophthalmic Inserts | |
| AU2007305205B2 (en) | Methods and ophthalmic devices used in the treatment of ocular allergies |